David Mayhew CBE - Chairman
David Mayhew CBE is former Chairman of J.P. Morgan Cazenove and now Vice Chairman of J.P. Morgan’s global investment bank and former Chairman of Cazenove Capital Holdings Ltd.
Besides excellence in his field, David also brings a strong personal commitment to driving forward Alzheimer’s Research UK to support new breakthroughs in dementia research and ultimately treatments to defeat dementia.
David was appointed by the Prime Minister as the new Dementia Envoy for the UK in March 2016. The role will see him work with organisations and leaders across the globe to promote the global fight against dementia. He will also play an important role in supporting the delivery of the 2020 Challenge on Dementia – the UK Government’s vision for tackling the condition over the next five years.
David is also a member of the Wellcome Trust Investment Committee, a Trustee of The Game and Wildlife Conservation Trust, a Trustee of David Rattray Memorial Trust and Member of the Takeover Panel Appeal Board.
Mike Cooper - Deputy Chairman
Mike Cooper started working in advertising in 1984 at Saatchi & Saatchi, he has also worked in television but has worked at Omnicom Group for the last 17 years. He became CEO of PHD Worldwide in 2007, responsible for growing the Omnicom owned network, which today has over 80 offices in 66 countries. Under Mike’s leadership, PHD was awarded AdWeek’s ‘Global Media Agency of the Year’ in 2012 and in 2013 was Campaign’s ‘Network of the Year’ runner-up as well as ‘Global Media Agency of the Year’ at the Cristal Awards in both 2013 and 2014.Today PHD is one of the world’s fastest growing and most awarded media agencies, with over 3,000 staff working for major global brands like Unilever, Hewlett Packard, GSK, Elizabeth Arden, Bayer, Canon, Porsche, Hyatt, and SAP.
Mike was appointed as Deputy Chairman in 2016.
Nick Antill - Treasurer
After beginning his career in the oil industry, Nick spent many years in the City of London where he was employed as an equity investment analyst specialising in valuing assets and companies in the oil and gas sector. He finished his career there as head of the European oil and gas equity research team at Morgan Stanley. Since the turn of the millennium he has been self-employed, working as a consultant both to the energy and to the investment industries, and as a financial trainer.
Dr Rupert Evenett is a social entrepreneur and has 30 years’ experience in investment markets and corporate finance. He has been a director in the UK civil service and is active in the voluntary sector, particularly in social investment and in charity strategy and governance, which he has combined with research in political philosophy on citizenship and social justice.
He was Chair of national volunteering charity The Conservation Volunteers (TCV), a director of The Social Investment Business, and is currently on the board of Goldsmiths, University of London and of the Old Royal Naval College, Greenwich.
Shirley Cramer CBE
Shirley is Chief Executive of the Royal Society for Public Health & Institute of Healthcare Management and is an experienced voluntary sector leader in both the UK and the USA and has also held non-executive positions in both countries in the public and voluntary sectors. She was Chief Executive of Dyslexia Action, the UK’s leading independent provider of services for individuals with dyslexia and other specific learning difficulties for over a decade. Prior to RSPH she was Interim Chief Executive of Alzheimer’s Research UK for six months and worked on the ‘Dementia Challenge’. She is Chair of the thinktank, British Future.
Shirley has a UK degree in Social Work and an MSc in Social Administration from Columbia University in New York.
Christopher brings a wealth of expertise from the financial sector. Since 2012 he has been a Senior Advisor to Morgan Stanley and prior to that served in a number of capacities for the company, including Vice Chairman – Institutional Securities, Head of Global Capital Markets and a member of the Firm’s Management Committee. He joined Morgan Stanley in 2006 from CQS, a hedge fund group, where he served as Chairman. He previously spent 19 years at Credit Suisse in a wide range of senior investment banking and executive positions. Christopher is Chaiman of Starcount Pte. and Artorius Wealth Management Limited.
Christopher became a Trustee of Alzheimer’s Research UK in 2015.
Giles joined the Board of Trustees in April 2017. He is a Partner at Simmons & Simmons, the international commercial law firm, and has been head of the UK Corporate Group since 2012. He focusses on general corporate, corporate governance and M&A advice for public and large private companies, and he has particular experience in the technology and life sciences sectors. He has worked in Hong Kong and London, including time spent on secondment within client organisations.
Caroline van den Brul, MBE
Caroline joined the Board of Trustees in April 2017. Caroline is a narrative-skills coach specialising in helping scientists communicate their ideas and the value of their work to colleagues, the public and funders. She had a distinguished 30-year career with the BBC as the creativity leader for the implementation of an ambitious culture-change programme, and as a programme maker. Her scores of credits include Tomorrow’s World, Horizon, Hospital Watch and The Ri Christmas Lectures.
As the 1993 Guardian Research Fellow, Caroline used a learning break at Nuffield College, Oxford, to research and publish a paper: Public Perceptions of Science. She is also the author of Crackle and Fizz: Essential Communication and Pitching Skills for Scientists, published in 2014.
Prof Rob Howard
Rob is Professor of Old Age Psychiatry at University College London and Honorary Consultant Psychiatrist at Camden and Islington NHS Trust. He has 30 years of experience of working clinically with people with dementia and in applied research to find and evaluate better treatments, both to modify the Alzheimer’s disease process and to improve the symptoms of dementia. Rob joined Alzheimer’s Research UK as a Trustee in 2018.
Dr Ruth McKernan CBE, FMedSci
Ruth is a neuroscientist with more than 25 years of research experience in the pharmaceutical industry. Her previous roles include Senior Vice President at Pfizer and Head of the Merck Neuroscience Research Centre. She spent the
last three years as CEO of InnovateUK, the Government’s Innovation agency helping to create new businesses and drive economic growth. Ruth has been a Council Member for the Medical Research Council and is a patron of the Spinal Research Trust. She was awarded a CBE in 2013 for services to business, innovation and skills. Ruth joined Alzheimer’s Research UK as a Trustee in 2018.